• PDH30- ROLE OF HRQL EVALUATION IN THE DRUG REGULATORY PROCESS- PRELIMINARY RESULTS FROM A EUROPEAN REGULATORY SURVEY

    Mar 1, 2000, 00:00

  • PDH6- ADVANTAGES AND LIMITS OF THE FRENCH HOSPITAL DATABASE (PMSI) ON DESCRIPTION OF HAEMOPHILIA MANAGEMENT AND COSTS

    Mar 1, 2000, 00:00

  • PDH29- FACTORS AFFECTING ASTHMATIC, DIABETIC, AND HYPERTENSIVE PATIENT SELF-REPORTED COMPLIANCE IN A PHARMACEUTICAL CARE DEMONSTRATION PROJECT

    Mar 1, 2000, 00:00

  • PCD12- SPIRONOLACTONE IN HEART FAILURE- LIFE AND COST SAVING TREATMENT IN POLAND

    Mar 1, 2000, 00:00

  • PMH34- CHARACTERIZATION AND ASSESSMENT OF DEPRESSION IN A CHRONIC NON-MALIGNANT PAIN POPULATION USING TWO DIFFERENT METHODOLOGIES IN A CLAIMS DATABASE

    Mar 1, 2000, 00:00

  • PMT12- DATA REQUIREMENTS OF SECOND-GENERATION ECONOMIC MODELS IN HIV/AIDS

    Mar 1, 2000, 00:00

  • PCDI7- THE EFFECTS OF PAYOR STATUS ON PROCEDURE USE AND OUTCOMES OF PATIENTS WITH CONGESTIVE HEART FAILURE

    Mar 1, 2000, 00:00

  • PDH13- QUALITY OF CARE INFERENCES FROM MULTIVARIATE ANALYSIS OF AMBULATORY DATA

    Mar 1, 2000, 00:00

  • PMW1- THE NEED FOR A QUALITY-OF-LIFE INSTRUMENT FOR ERECTILE DYSFUNCTION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Mar 1, 2000, 00:00

  • PDH8- SUBSPECIALISTS- DO THEY PROVIDE BETTER QUALITY AND MORE EFFICIENT CARE? AN ANALYSIS OF OUTCOMES DATA FROM 6 HOSPITALS

    Mar 1, 2000, 00:00

  • ICP3- FACTORS INFLUENCING PATIENT WILLINGNESS TO PAY FOR DIABETES DISEASE STATE MANAGEMENT PROGRAMS

    Mar 1, 2000, 00:00

  • CEB3- COST-EFFECTIVENESS OF PREVENTION OF CORONARY HEART DISEASE (CHD) WITH SIMVASTATIN IN POLAND

    Mar 1, 2000, 00:00

  • PMT21- DERIVING HEALTH UTILITIES FROM EFFICACY OUTCOME SCALES IN ALZHEIMERS DISEASE (AD)

    Mar 1, 2000, 00:00

  • PCD13- COST-EFFECTIVENESS ANALYSIS OF ENALAPRIL IN THE MANAGEMENT OF CHF IN POLAND

    Mar 1, 2000, 00:00

  • PCD9- COST-EFFECTIVENESS OF RAMIPRIL IN HYPERTENSIVE PATIENTS WITH NEPHROPATHY IN GERMANY

    Mar 1, 2000, 00:00

  • PCN13- COLONOSCOPY CHARGES IN A MANAGED CARE POPULATION- DIFFERENCES BASED ON POLYPECTOMY AND MALIGNANCY STATUS

    Mar 1, 2000, 00:00

  • PCD19- RELATIONSHIP BETWEEN DAILY DOSE FREQUENCY AND ADHERENCE TO ANTIHYPERTENSIVE PHARMACOTHERAPY- UPDATE OF A META-ANALYSIS

    Mar 1, 2000, 00:00

  • PSG13- PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING- TESTING THE VALUE OF A DOLASETRON-BASED ALGORITHM

    Mar 1, 2000, 00:00

  • POS1- THE BURDEN OF OSTEOPOROSIS TO THE STATE OF FLORIDA- PROJECTIONS FOR 2000-2010

    Mar 1, 2000, 00:00

  • DH3- PUBLIC REPORT SPURS HOSPITAL MORTALITY REDUCTION

    Mar 1, 2000, 00:00

  • BT2- DIRECT COSTS OF OBESITY IN PORTUGAL

    Mar 1, 2000, 00:00

  • PMT18- BIAS ARISING FROM MISSING DATA IN A RETROSPECTIVE STUDY OF THE OUTCOMES OF INTRA-ABDOMINAL INFECTIONS

    Mar 1, 2000, 00:00

  • PHV19- IMPACT OF ANTIBIOTIC CHOICE ON COSTS, OUTPATIENT VISITS, AND 28-DAY OUTCOMES FOR COMMUNITY-ACQUIRED PNEUMONIA PATIENTS

    Mar 1, 2000, 00:00

  • PRN5- QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILIZATION IN OVERACTIVE BLADDER PATIENTS WITH URGE INCONTINENCE

    Mar 1, 2000, 00:00

  • S4- METHODS FOR COMPARING AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES- APPLICATION IN SCREENING ACCURACY FOR DEPRESSION

    Mar 1, 2000, 00:00

  • PDB5- COST-EFFECTIVENESS OF RENTINOPATHY SCREENING IN PEDIATRIC PATIENTS WITH TYPE I DIABETES MELLITUS

    Mar 1, 2000, 00:00

  • PSG10- RESTENOSIS AND MEDICAL COSTS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) WITH AND WITHOUT STENT

    Mar 1, 2000, 00:00

  • ICP4- HEALTH STATE PREFERENCES IN DIABETIC PERIPHERAL NEUROPATHY

    Mar 1, 2000, 00:00

  • PDH28- A DRUG COST MODEL FOR A CAPITATED PATIENT POPULATION WITHIN AN INTEGRATED HEALTH CARE SYSTEM

    Mar 1, 2000, 00:00

  • PMH35- ECONOMIC OUTCOMES WITH NEWER ANTIDEPRESSANTS FOR THE TREATMENT OF DEPRESSION IN A COMMERCIALLY-INSURED POPULATION

    Mar 1, 2000, 00:00

  • PDH14- COMPLIANCE AND PERSISTENCY BENEFITS ACHIEVED BY UTILIZING A ONCE DAILY EXTENDED RELEASE MEDICATION VS. A TWICE DAILY REGIMEN

    Mar 1, 2000, 00:00

  • PDH24- PHARMACEUTICAL INDUSTRY PERCEPTIONS OF THE USE OF PHARMACOECONOMIC DATA BY HEALTH CARE ORGANIZATIONS

    Mar 1, 2000, 00:00

  • PRS5- IMPACT OF INHALED CORTICOSTEROIDS (FLUTICASONE PROPIONATE) ON ECONOMIC OUTCOMES IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PMH27- THE IMPACT OF DEPRESSION ON HEALTH-RELATED QUALITY OF LIFE (HRQL)

    Mar 1, 2000, 00:00

  • PCD1- INCORPORATING BOTH DIASTOLIC AND SYSTOLIC PRESSURES IN A MODEL OF THE BENEFITS OF ACHIEVING HYPERTENSION TREATMENT TARGETS

    Mar 1, 2000, 00:00

  • PHV17- PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF ADULT PERTUSSIS BOOSTER VACCINATION

    Mar 1, 2000, 00:00

  • PMH23- HOW MUCH CHANGE IN QUALITY OF LIFE AND SYMPTOM SCORES REPRESENTS A DETECTABLE DIFFERENCE FOR SCHIZOPHRENIA PATIENTS?

    Mar 1, 2000, 00:00

  • PMT19- NON-RANDOMIZED STUDIES COMPARING OLANZAPINE AND RISPERIDONE- BASELINE SIMILARITIES AND DIFFERENCES

    Mar 1, 2000, 00:00

  • PMT32- UTILITY ESTIMATION USING THE EQ-5D- EXPERT PANEL DATA AND ALTERNATIVE METHODS OF SYNTHESIS

    Mar 1, 2000, 00:00

  • PCD7- SOCIECONOMIC EVALUATION OF CILOSTAZOL FOR THE SECONDARY PREVENTION OF CEREBRAL INFARCTION IN JAPAN

    Mar 1, 2000, 00:00

  • PRS4- IDENTIFYING PREDICTORS OF THE ASTHMA-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE-AMERICAN ADULTS (AQLQ-NAA)

    Mar 1, 2000, 00:00

  • PHV13- COST ANALYSIS OF CEFTRIAXONE VERSUS CEFTRIAXONE PLUS MACROLIDE TREATMENT FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    Mar 1, 2000, 00:00

  • PDB11- EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM IN A NURSING HOME

    Mar 1, 2000, 00:00

  • R2- RISK FACTORS FOR SHORT-TERM DIABETES COMPLICATIONS- AN ANALYSIS OF LINKED ADMINISTRATIVE CLAIMS AND CLINICAL LABORATORY DATA

    Mar 1, 2000, 00:00

  • PHV15- CLINICAL AND ECONOMIC BENEFITS OF THE PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN

    Mar 1, 2000, 00:00

  • DH1- AN ANALYSIS OF THE IMPACT OF MEDICATION NON-ADHERENCE AND TYPE OF MEDICATION ON OUTCOME DOMAINS USING THE SCAP HEALTH QUESTIONNAIRE

    Mar 1, 2000, 00:00

  • MI3- RELIABILITY AND VALIDITY OF INTERNATIONAL PROSTATE SYMPTOM SCORE (l-PSS) FOR EARLY ASSESSMENT OF SYMPTOMS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA (BPH)

    Mar 1, 2000, 00:00

  • PRN4- ASSESSING QUALITY OF LIFE IN ROUTINE CLINICAL PRACTICE- A PILOT STUDY IN PATIENTS WITH RENAL DISEASE

    Mar 1, 2000, 00:00

  • PDH11- EVALUATION OF CIGARETTE SMOKERS PERCEPTIONS OF SMOKING CESSATION AND THE ROLE OF HEALTH CARE PROFESSIONALS

    Mar 1, 2000, 00:00

  • PHV4- HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH FOUR CATEGORIES OF SKIN ULCERS IN NEW MEXICO MEDICAID PATIENTS

    Mar 1, 2000, 00:00

  • S1- IMPACT OF COMMUNITY-ACQUIRED PNEUMONIA TREATMENT GUIDELINES ON LENGTH OF STAY AND COST

    Mar 1, 2000, 00:00

  • PHH9- A MANAGED CARE VALIDATION PROGRAM FOR A PHARMACOECONOMIC MODEL OF MAJOR DEPRESSION

    Mar 1, 2000, 00:00

  • PMT13- TRANSFERING THE RESULTS FROM ECONOMIC EVALUATIONS- THE USE OF BASILIXIMAB IN TRANSPLANT PATIENTS

    Mar 1, 2000, 00:00

  • PCD18- THE PERCEPTUAL EFFECTIVENESS INDEX- A NEW APPROACH FOR EVALUATING OUTCOMES OF ANTI-HYPERTENSIVE THERAPY

    Mar 1, 2000, 00:00

  • PMH32- QUANTIFYING THE ECONOMIC IMPACT OF POTENTIAL DRUG INTERACTIONS IN THE TREATMENT OF DEPRESSION

    Mar 1, 2000, 00:00

  • PHV24- DISCRIMINATIVE ABILITY OF THE SF-12 IN A SAMPLE OF PERSONS WITH HIV

    Mar 1, 2000, 00:00

  • PMH2- ESTIMATED COSTS OF TREATMENT FOR BIPOLAR AFFECTIVE DISORDER IN A LARGE EMPLOYER DATABASE

    Mar 1, 2000, 00:00

  • Q2- PATIENT PREFERENCES FOR TREATMENT OUTCOMES IN DISABLING TREMOR

    Mar 1, 2000, 00:00

  • D1- DEVELOPMENT AND VALIDATION OF A SCREENING INSTRUMENT FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    Mar 1, 2000, 00:00

  • PCD15- HOW MEANINGFUL ARE THE CORONARY BENEFITS OF SELECTIVE ESTROGEN RECEPTOR MODULATORS?

    Mar 1, 2000, 00:00

  • PMW6- MATCHING VA UROLOGISTS PREFERENCES IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA WITH CLINICAL PRACTICE GUIDELINES

    Mar 1, 2000, 00:00

  • PRS1- DIRECT AND INDIRECT COSTS OF ASTHMA TO AN EMPLOYER

    Mar 1, 2000, 00:00

  • PHT17- DEALING WITH SKEWED DATA- AN EXAMPLE USING ASTHMA-RELATED COSTS OF MEDICAID CLIENTS

    Mar 1, 2000, 00:00

  • PMW2- DOES TESTOSTERONE AFFECT HEALTH-RELATED QUALITY OF LIFE IN HEALTHY, ELDERLY MALES?-A PILOT STUDY

    Mar 1, 2000, 00:00

  • PWP5- WORK PRODUCTIVITY EFFECTS OF DIABETES- IMPLICATIONS FOR RESEARCH AND POLICY

    Mar 1, 2000, 00:00

  • PMT31- AN ASSESSMENT OF COST-UTILITY OF PATIENTS FROM SF-36 SCORES USING THE BEAVER DAM HEALTH OUTCOMES STUDY METHOD

    Mar 1, 2000, 00:00

  • PMT34- ASSESSING PHYSICIAN PRACTICE PROFITABILITY USING AN ACTIVITY BASED COSTING MODEL

    Mar 1, 2000, 00:00

  • PMH21- COMMUNITY PHARMACIST ASSESSMENT OF THE QUALITY OF LIFE OF TREATED AMBULATORY DEPRESSED PATIENTS

    Mar 1, 2000, 00:00

  • PWP4- A WILLINGNESS-TO-PAY ASSESSMENT OF TWO TREATMENTS FOR OBESITY

    Mar 1, 2000, 00:00

  • PCH4- APPLICATION OF PHARMACOECONOMICS AND OUTCOMES RESEARCH ON DECISION-MAKING PATTERNS BY MEDICAL ONCOLOGISTS

    Mar 1, 2000, 00:00

  • PHV8- UNCOMPLICATED ACUTE PYELONEPHRITIS IN ADULT WOMEN- INPATIENT VERSUS OUTPATIENT THERAPY -ECONOMIC COMPARISON

    Mar 1, 2000, 00:00

  • PDH1O- POTENTIAL VALUE FOR MONEY OF RESEARCH- BETA INTERFERON AND THE UK-MS STUDY

    Mar 1, 2000, 00:00

  • CEB4- THE COST-EFFECTIVENESS OF FIXED-DOSE COMBINATION OF DICLOFENAC AND MISOPROSTOL IN PREVENTION OF NSAID-INDUCED ULCERS IN RHEUMATOID ARTHRITIS PATIENTS IN POLAND

    Mar 1, 2000, 00:00

  • S3- STATISTICAL METHOD FOR MODELING DUAL SELECTION BIAS- WOODWORK EFFECT AND DRUG SELECTION BIAS AMONG MULTIPLE ALTERNATIVES

    Mar 1, 2000, 00:00

  • POS2- INTEREST OF THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) TOOL FOR A MORE RATIONAL USE OF BONE DENSITOMETRY

    Mar 1, 2000, 00:00

  • DUC3- SMOKING CESSATION SUCCESS RATES WITH DRUG THERAPY IN A SAMPLE OF MEDICAID PATIENTS

    Mar 1, 2000, 00:00

  • PDH16- IDENTIFYING PATIENTS WITH PSYCHOSES IN A MEDICAID MANAGED CARE ORGANIZATION WITH CARVED-OUT BEHAVIORAL HEALTH SERVICES

    Mar 1, 2000, 00:00

  • PMT1O- MODELLING ISSUES- FIRST EPISODE SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • CAN3- BASELINE COST OF ILLNESS OF PARKINSONS DISEASE IN A LARGE HEALTHCARE PLAN

    Mar 1, 2000, 00:00

  • PSC7- POSTOPERATIVE PAIN RELIEF, INTERFERENCE WITH ACTIVITIES, AND SATISFACTION- PRELIMINARY RESULTS

    Mar 1, 2000, 00:00

  • PMH39- HEALTH CARE BURDEN AND COST OF PARKINSONS DISEASE

    Mar 1, 2000, 00:00

  • DUC1- DRUG UTILIZATION OF CISAPRIDE AND CONTRAINDICATED DRUGS IN A US MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PCD21- TWO-YEAR MEDICATION COMPLIANCE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

    Mar 1, 2000, 00:00

  • CEB7- SOCIOECONOMIC EFFICIENCY OF THE ADJUVANT TREATMENT WITH ACAMPROSATE IN MAINTAINING ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS

    Mar 1, 2000, 00:00

  • PHV25- QUALITY OF LIFE OF ADULT PATIENTS TREATED FOR A RESPIRATORY TRACT INFECTION

    Mar 1, 2000, 00:00

  • CEB8- A DECISION ANALYTIC MODEL MEASURING THE COST-EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HIV PATIENTS WITH HIGH VERSUS LOW BASELINE VIRAL LOAD- AN INDINAVIR PLUS LAMIVUDINE ANDZIDOVUDINE EXAMPLE

    Mar 1, 2000, 00:00

  • PSG14- COST-EFFECTIVE STRATEGIES- ASSESSING PHARMACISTS INTERVENTION IN A COMMUNITY HOSPITAL INTENSIVE CARE UNIT

    Mar 1, 2000, 00:00

  • PWP6- A PRELIMINARY STUDY OF PROVISION OF PHARMACEUTICAL CARE IN COMMUNITY PHARMACY IN SINGAPORE- COST ANALYSIS PATIENT WILLINGNESS TO PAY

    Mar 1, 2000, 00:00

  • PCD14- TREATMENT COST OF SIDE EFFECTS OF ANTIARRHYTHMIC DRUGS IN THE USA

    Mar 1, 2000, 00:00

  • PDH17- ARE THE BRITISH GOVERNMENTS NEEDS?- EVIDENCE FROM A COMPARISON OF TWO GP SURVEYS ON MUSCULOSKELETAL CARE

    Mar 1, 2000, 00:00

  • PAR2- PHARMACOECONOMICAL ANALYSIS OF NON-STEROID ANTI-INFLAMMATORY DRUGS IN RHEUMATOLOGY

    Mar 1, 2000, 00:00

  • PMH1- RECENT TRENDS IN THE COST OF CARE FOR PATIENTS WITH SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PMH3- ALZHEIMERS DISEASE COST OF CARE IN MANAGED CARE

    Mar 1, 2000, 00:00

  • PMH37- EVALUATING HEALTHCARE RESOURCE UTILIZATION IN A POPULATION OF MIGRAINE PATIENTS USING SUMATRIPTAN AND NON-SUMATRIPTAN PHARMACEUTICALS

    Mar 1, 2000, 00:00

  • PHV20- COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE TREATMENT IN CHRONIC HEPATITIS B

    Mar 1, 2000, 00:00

  • PMT26- FIELLERS INTERVAL, ITS EXTENSIONS AND THEIR APPLICATIONS IN COST-EFFECTIVENESS ANALYSES

    Mar 1, 2000, 00:00

  • PDH18- ENTER THE DRAGON- PHARMACOECONOMICS IN ASIA

    Mar 1, 2000, 00:00

  • PCD3- PROSPECTIVE EVALUATION OF AN INFORMATION DISSEMINATION PROGRAM INCORPORATING PEER COMPARISON FEEDBACK IN PEPTIC ULCER DISEASE MANAGEMENT

    Mar 1, 2000, 00:00

  • PNH6- PHARMACOECONOMIC ANALYSES OF DEPOT NEUROLEPTIC TREATMENT IN NATURAL SETTING

    Mar 1, 2000, 00:00

  • PMT16- ESTIMATION OF ANNUAL CARDIOVASCULAR RISK IN PILOTS

    Mar 1, 2000, 00:00

  • PDH25- A QUALITATIVE ASSESSMENT OF MANAGED CARE DECISION-MAKERS VIEWS AND USE OF PHARMACOECONOMIC INFORMATION

    Mar 1, 2000, 00:00

  • PHV3- MODELLING A COST-OF-ILLNESS STUDY TO EVALUATE THE BURDEN OF INFLUENZA IN ITALY

    Mar 1, 2000, 00:00

  • PHV9- COST OF TREATING HISPANIC PATIENTS WITH AIDS IN US HOSPITALS

    Mar 1, 2000, 00:00

  • PHV1- UTILIZATION OF INTENSIVE CARE AND HOSPITAL DAYS AND OUTCOME IN PATIENTS WITH SEVERE SEPSIS- THE SELECT II REGISTRY

    Mar 1, 2000, 00:00

  • PCN1O- PSYCHOMETRIC VALIDITY OF QUALITY OF LIFE AND UTILITY MEASURES IN NON-SMALL CELL LUNG CANCER (NSCLC)- A LITERATURE REVIEW

    Mar 1, 2000, 00:00

  • PDH12- A RANDOMIZED CONTROLLED MULTI-CENTER STUDY EVALUATING THE EFFECT OF PHARMACEUTICAL CARE ON CHANGES IN QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PRS9- PREDICTORS OF HOSPITALIZATION AND EMERGENCY ROOM USE IN A MEDICAID MANAGED CARE ASTHMATIC POPULATION

    Mar 1, 2000, 00:00

  • PMH25- THE IMPACT OF SCHIZOPHRENIA ON HEALTH-RELATED QUALITY OF LIFE (HRQL) FOR PATIENTS ADMITTED TO PSYCHIATRIC UNITS OF GENERAL ACUTE CARE HOSPITALS

    Mar 1, 2000, 00:00

  • PRN7- RELIABILITY OF REPORTING ON COPING STRATEGIES AND IMPACT OF OVERACTIVE BLADDER

    Mar 1, 2000, 00:00

  • PSG11- COST ANALYSIS OF INHALED AGENTS IN CANADIAN PEDIATRIC HOSPITALS

    Mar 1, 2000, 00:00

  • PCH8- PHARMACOECONOMICS OF COMBINATION OF CHEMOTHERAPY WITH DOCETAXEL IN ADVANCED BREAST CANCER

    Mar 1, 2000, 00:00

  • PRS2- IMPACT OF A TARGETED ASTHMA INTERVENTION PROGRAM ON TREATMENT COSTS

    Mar 1, 2000, 00:00

  • PMH36- CONFORMANCE WITH ANTIPSYCHOTIC DRUG THERAPY GUIDELINES FOR TREATING SCHIZOPHRENIA IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM

    Mar 1, 2000, 00:00

  • PDB1- RESOURCE USE AND COST ASSOCIATED WITH MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES

    Mar 1, 2000, 00:00

  • PCD6- COST ANALYSIS OF ANTIHYPERTENSIVE DRUG USE IN TURKEY

    Mar 1, 2000, 00:00

  • Economic Evaluation of Letrozole in the Treatment of Advanced Breast Cancer in Postmenopausal Women in Canada

    Jan 1, 2000, 00:00

  • Evaluation of Therapeutic Strategies- A New Method for Balancing Risk and Benefit

    Jan 1, 2000, 00:00

  • Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer

    Jan 1, 2000, 00:00

  • A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium

    Jan 1, 2000, 00:00

  • Economic Assessment of a Maintenance Treatment Strategy in Prevention of Recurrent Depressive Disorder

    Jan 1, 2000, 00:00

  • Estimating Endogenous Treatment Effects in Retrospective Data Analysis

    Nov 1, 1999, 00:00

  • Health Care Costs and Outcomes- How Should We Evaluate Real World Data?

    Nov 1, 1999, 00:00

  • Incontinence Drug Utilization Patterns in Québec, Canada

    Nov 1, 1999, 00:00

  • Stochastic Cost-Effectiveness Analysis- A Simultaneous Marginal-Effect Approach

    Nov 1, 1999, 00:00

  • Controlling for Systematic Selection in Retrospective Analyses- An Application to Fluoxetine and Sertraline Prescribing in the United Kingdom

    Nov 1, 1999, 00:00

  • Noncompliance with Drug Therapy for Chronic Obstructive Pulmonary Disease- A Risk Factor for Hospitalization?

    Nov 1, 1999, 00:00

  • TPM5- BURDEN OF BRONCHIAL ASTHMA- FAMILY EXPENSES FOR CHILDS DISEASE

    Sep 1, 1999, 00:00

  • PCV9- COST-COMPARISON ANALYSIS OF HOME MONITORING AND AMBULANT MONITORING OF ORAL ANTICOAGULATION IN SWITZERLAND

    Sep 1, 1999, 00:00

  • SD4- QUALITY OF LIFE ASSESSMENT AS A NEW OUTCOME MEASURE IN CLINICAL PRACTICE

    Sep 1, 1999, 00:00

  • CV4- THE COST OF HYPERTENSION AND ITS CORRELATES IN EMILIA ROMAGNA REGION (ITALY)- RESULTS FROM THE GREAT STUDY

    Sep 1, 1999, 00:00

  • PCV1- DIRECT COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS- A MODELING APPROACH

    Sep 1, 1999, 00:00

  • QL4- USING RASCH MODELS TO IMPROVE THE EVALUATIVE-SCALE PROPERTIES OF THE WOMENS HEALTH QUESTIONNAIRE

    Sep 1, 1999, 00:00

  • CN2- AN ECONOMIC COMPARISON OF OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE

    Sep 1, 1999, 00:00

  • PEN2- METHODOLOGICAL ASPECTS OF MULTI COUNTRY COST OF ILLNESS STUDIES-2- INTERNET BASED DATA MANAGEMENT

    Sep 1, 1999, 00:00

  • GI4- PREDICTORS OF SAMPLE INCLUSION FOLLOWING THE APPLICATION OF CONTINUOUS ELIGIBILITY REQUIREMENTS IN SUBJECTS RECEIVING COLONOSCOPIES

    Sep 1, 1999, 00:00

  • CA2- COST COMPARISONS BETWEEN HOSPITALS IN DIFFERENT COUNTRIES BY MEANS OF A RESOURCE USE INDEX

    Sep 1, 1999, 00:00

  • TPC4- AN ECONOMIC EVALUATION OF AMLODIPINE FOR THE TREATMENT OF NONISCHEMIC DILATED CARDIOMYOPATHY- THE PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION (PRAISE)

    Sep 1, 1999, 00:00

  • PGI1- EFFECTIVENESS OF OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN IN ERADICATING HELICOBACTER PYLORI IN PATIENTS ON CHRONIC ACID SUPPRESSION FOR PEPTIC ULCER DISEASE OR ULCER-LIKE SYMPTOMS

    Sep 1, 1999, 00:00

  • PCA2- IRINOTECAN IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER- IMPROVED SURVIVAL AND COST EFFECTIVENESS COMPARED WITH INFUSIONAL 5-FLUOROURACIL

    Sep 1, 1999, 00:00

  • TPQ3- EUROPEAN GUIDANCE DOCUMENT FOR THE IMPROVEMENT OF THE INTEGRATION OF HEALTH-RELATED QUALITY OF LIFE (HRQL) ASSESSMENT IN THE DRUG REGULATORY PROCESS

    Sep 1, 1999, 00:00

  • QL3- ANTIPSYCHOTIC TREATMENT AND CHANGES IN HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA USING EQ-5D

    Sep 1, 1999, 00:00

  • The Influence of Case Mix, Site Selection, and Methods Biases on Costs of Hospitalization For Acute Exacerbations of Chronic Obstructive Airways Disease and Lower Respiratory Tract Infections

    Sep 1, 1999, 00:00

  • SD1- USING CONJOINT ANALYSIS TO ASSESS WOMENS PREFERENCES FOR MATERNITY CARE SERVICES DURING THE INTRAPARTUM STAGE

    Sep 1, 1999, 00:00

  • ED4- QUALITY OF LIFE AND USE OF HEALTHCARE RESOURCES IN GROWTH HORMONE-DEFICIENT ADULTS AFTER GROWTH HORMONE REPLACEMENT THERAPY

    Sep 1, 1999, 00:00

  • TPC2- COST-MINIMIZATION ANALYSIS OF TWO TRIPLE REGIMENS FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED PEPTIC ULCER DISEASE

    Sep 1, 1999, 00:00

  • PTH4- ECONOMIC EVALUATION BY UK PHARMACEUTICAL AND MEDICAL DEVICE FIRMS- GENERAL TRENDS AND POLICY IMPLICATIONS

    Sep 1, 1999, 00:00

  • PID2- ASSESSING THE DIRECT COST OF LYME DISEASE

    Sep 1, 1999, 00:00

  • CN7- REDUCING ANTICHOLINERGIC ANTIDEPRESSANT USE IN THE ELDERLY- A RANDOMIZED TRIAL OF GROUP VERSUS INDIVIDUAL 'ACADEMIC DETAILING'

    Sep 1, 1999, 00:00

  • SR3- DEVELOPMENT AND VALIDATION OF THE QUALITY OF LIFE WITH MIGRAINE (QOLWM)- A BRIEF MIGRAINE SURVEY

    Sep 1, 1999, 00:00

  • PCV10- PREDICTORS OF ADHERENCE TO LIPID-LOWERING THERAPY

    Sep 1, 1999, 00:00

  • TPE3- ECONOMIC EVALUATION OF DIFFERENT STRATEGIES OF A VACCINATION AGAINST HEPATITIS A AND HEPATITIS B

    Sep 1, 1999, 00:00

  • PID6- TREATMENT OF ACUTE OTITIS MEDIA IN A MANAGED CARE POPULATION

    Sep 1, 1999, 00:00

  • ED3- DEALING WITH CO-MORBIDITY AND RARE COMPLICATIONS IN A DIABETES TYPE 2 COST OF ILLNESS STUDY

    Sep 1, 1999, 00:00

  • CN3- COST-EFFECTIVENESS OF RT-PA IN TREATMENT OF ACUTE ISCHAEMIC STROKE IN UK

    Sep 1, 1999, 00:00

  • PTH12- INTENSIVE CARE COSTS OF TREATING PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME- HOW CAN THESE BE MEASURED?

    Sep 1, 1999, 00:00

  • ED1- COST-EFFECTIVENESS OF INTENSIVE METFORMIN VERSUS CONVENTIONAL THERAPY FOR OBESE PATIENTS WITH TYPE 2 DIABETES

    Sep 1, 1999, 00:00

  • PID5- RETROSPECTIVE STUDY COMPARING COST-EFFECTIVENESS OF NEWER AMPHOTERICIN B PREPARATIONS

    Sep 1, 1999, 00:00

  • TPL3- BEST EVIDENCE IN PHARMACOECONOMICS

    Sep 1, 1999, 00:00

  • CN5- THE COST OF INPATIENT TREATMENT OF SCHIZOPHRENIA- A STUDY OF TWO LEADING ATYPICAL ANTIPSYCHOTICS

    Sep 1, 1999, 00:00

  • PTH2- MALIGNANT RETROPERITONEAL TUMOURS OF CHILDREN- FIRST RESEARCH OF QUALITY OF LIFE OF 278 SURVIVED PATIENTS

    Sep 1, 1999, 00:00

  • TPP1- IMPLEMENTING A MODEL OF RISK SHARING OF PHARMACEUTICAL BENEFITS IN PRIMARY CARE

    Sep 1, 1999, 00:00

  • CV6- COST-EFFECTIVENESS OF STATINS- MOVING BEYOND THE PRIMARY AND SECONDARY PREVENTION DISTINCTION

    Sep 1, 1999, 00:00

  • CA3- ESTIMATING SURVIVAL GAIN FOR COST-EFFECTIVENESS ANALYSIS- THE EXAMPLE OF EARLY HORMONAL TREATMENT IN LOCALLY ADVANCED PROSTATE CANCER

    Sep 1, 1999, 00:00

  • PG15- COST OF ILLNESS STUDIES MAY LARGELY UNDERESTIMATE THE COST OF DISEASES WITH UNMET MEDICAL NEED SUCH AS IRRITABLE BOWEL SYNDROME (IBS)

    Sep 1, 1999, 00:00

  • PCN3- COST ANALYSIS OF SCHIZOPHRENIA TREATMENT IN GERMANY- A COMPARISON OF OLANZAPINE, RISPERIDONE, AND HALOPERIDOL USING A CLINICAL DECISION MODEL

    Sep 1, 1999, 00:00

  • TPQ2- A REVIEW OF AVAILABLE HEALTH-RELATED QUALITY OF LIFE (HRQL) REFERENCE VALUES IN THE MEDICAL LITERATURE

    Sep 1, 1999, 00:00

  • PID1- ESTIMATES OF THE INDIRECT COSTS OF HIV AND AIDS IN THE UNITED KINGDOM

    Sep 1, 1999, 00:00

  • PEN3- DEVELOPMENT OF AN ALGORITHM FOR ESTIMATING ASTHMA SEVERITY FROM AN ADMINISTRATIVE COST DATABASE

    Sep 1, 1999, 00:00

  • CV2- AN ECONOMIC ASSESSMENT OF DALTEPARIN VERSUS WARFARIN IN TOTAL HIP REPLACEMENT

    Sep 1, 1999, 00:00

  • GI3- EVALUATION OF PHARMACISTS INTERVENTIONS ON PRESCRIBING ERRORS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS- COSTS SAVINGS AND CLINICAL EFFECTS

    Sep 1, 1999, 00:00

  • PTH1- USE OF ADMINISTRATIVE DATA FOR POST-MARKET SURVEILLANCE OF THE OUTCOME OF TOTAL HIP AND KNEE REPLACEMENTS

    Sep 1, 1999, 00:00

  • PMW4- A MICRO-COST ANALYSIS OF URINARY INCONTINENCE CARE IN LONG-TERM CARE FACILITIES

    Sep 1, 1999, 00:00

  • SR2- A PHARMACO-ECONOMIC CASE STUDY IN ANAESTHESIA, INCLUDING A RECENT RE-ANALYSIS USING BOOTSTRAP TECHNIQUES

    Sep 1, 1999, 00:00

  • IR3- COST OF NOSOCOMIAL PNEUMONIA IN A LARGE TEACHING HOSPITAL

    Sep 1, 1999, 00:00

  • PEN4- MEASURING THE REAL ANNUAL DIRECT COSTS OF DIABETES TYPE 2 PATIENTS IN GERMANY

    Sep 1, 1999, 00:00

  • PCA1- PHARMACOECONOMIC EVALUATION OF FILGRASTIM (r-metHuG-CSF) TREATMENT IN AUTOLOGOUS BONE MARROW TRANSPLANTATION

    Sep 1, 1999, 00:00

  • PCN7- ECONOMIC ASPECTS OF AN INTERNATIONAL STUDY OF MAJOR DEPRESSIVE DISORDER IN PRIMARY CARE PATIENTS (THE LIDO STUDY)

    Sep 1, 1999, 00:00

  • IR2- THE COSTS OF THE INADEQUATE USE OF ANTIBIOTICS

    Sep 1, 1999, 00:00

  • SD3- USING ECONOMIC INFORMATION IN HOSPITAL FORMULARY DECISION-MAKING

    Sep 1, 1999, 00:00

  • CN1- COSTS OF DEMENTIA IN GERMANY-AN ANALYSIS OF 7490 HEALTH INSURANCE FILES

    Sep 1, 1999, 00:00

  • GI1- COST-EFFECTIVENESS OF THE COMBINATION OF MISOPROSTOL WITH DICLOFENAC IN THE TAYSIDE POPULATION

    Sep 1, 1999, 00:00

  • TPL2- MULTINATIONAL ECONOMIC EVALUATIONS- A REVIEW OF PUBLISHED STUDIES, METHODOLOGICAL ISSUES AND PRACTICE

    Sep 1, 1999, 00:00

  • TPC3- COST OF AML TREATMENT IN BELGIUM- RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE

    Sep 1, 1999, 00:00

  • CA1- PROSPECTIVE ECONOMIC EVALUATION OF ANTIBIOTIC PROPHYLAXIS IN SMALL CELL LUNG CANCER (SCLC) PATIENTS RECEIVING CHEMO THERAPY

    Sep 1, 1999, 00:00

  • PCV6- COST OF SECOND LINE PHARMACEUTICAL MANAGEMENT OF ATRIAL FIBRILLATION IN FRANCE

    Sep 1, 1999, 00:00

  • PTH9- RETROSPECTIVE OUTCOMES ANALYSIS OF THE EFFECTS OF ZAFIRLUKAST THERAPY IN THE MANAGEMENT OF PATIENTS WITH ASTHMA IN THE UNITED STATES

    Sep 1, 1999, 00:00

  • PCN6- MODELLING THE LONG-TERM COST EFFECTIVENESS OF RILUZOLE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

    Sep 1, 1999, 00:00

  • ED2- COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS

    Sep 1, 1999, 00:00

  • TPP2- EVALUATION OF A THERAPEUTIC INTERCHANGE PROGRAM FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION

    Sep 1, 1999, 00:00

  • PTH7- GLOBAL SCALE VERSUS GENERIC AND DISEASE-SPECIFIC INSTRUMENTS TO MEASURE THE HEALTH STATUS OF PATIENTS WITH ASTHMA

    Sep 1, 1999, 00:00

  • PCA6- COST OF POSTMENOPAUSAL BREAST CANCER IN BELGIUM- AN INCIDENCE BASED APPROACH

    Sep 1, 1999, 00:00

  • PCN12- HEALTH ECONOMICS FOR N-OF-1 TRIALS

    Sep 1, 1999, 00:00

  • PCV3- COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER IN THE UNITED STATES

    Sep 1, 1999, 00:00

  • TPM2- ONE-YEAR REHOSPITALISATION RATE IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

    Sep 1, 1999, 00:00

  • PCV7- AN ECONOMIC ANALYSIS OF TELMISARTAN (MICARDIS) TREATMENT FOR PEOPLE WITH MILD TO MODERATE HYPERTENSION IN THE UK

    Sep 1, 1999, 00:00

  • QL5- ASTHMA BOTHER PROFILE VERSUS AIRWAY QUESTIONNAIRE 20 AS SIMPLE MEASURES TO EVALUATE THE HEALTH STATUS IN ASTHMA

    Sep 1, 1999, 00:00

  • PEN1- QUALITY-OF-LIFE-EVALUATION OF THE GERMAN S.A.T.-TRIAL - COMPARISON OF SF-36, EUROQOL, TIME-TRADE-OFF METHOD AND WILLINGNESS-TO-PAY

    Sep 1, 1999, 00:00

  • CN8- PRODUCTIVITY COST MEASUREMENT- EMPIRICAL ANALYSIS OF QALY, HUMAN CAPITAL AND FRICTION COST METHODOLOGIES

    Sep 1, 1999, 00:00

  • PCV11- STUDY OF HEALTH CARE RESOURCE USE FOR ELDERLY PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION

    Sep 1, 1999, 00:00

  • PCN8- ANTIPSYCHOTIC DRUG USE AND HOSPITALISATION IN PATIENTS WITH SCHIZOPHRENIA

    Sep 1, 1999, 00:00

  • CN4- ECONOMIC APPROACH FOR ASSESSING THE OVERALL COST OF MANAGING ISCHEMIC EVENTS (MYOCARDIAL INFARCTION STROKE) IN ATHEROTHROMBOTIC PATIENTS- A EUROPEAN OVERVIEW

    Sep 1, 1999, 00:00

  • PCV4- COST ANALYSIS OF AMLODIPINE VERSUS FELODIPINE ER IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION

    Sep 1, 1999, 00:00

  • PCN10- A CROSS-SECTIONAL ANALYSIS OF HEALTH CARE COST OF SSRI USERS

    Sep 1, 1999, 00:00

  • PCN4- A COMPARISON OF ADULT MIGRAINE TREATMENT REGIMENS IN A MANAGED CARE POPULATION

    Sep 1, 1999, 00:00

  • TPM3- THE EFFECT OF OBSERVATION DURATION ON CLAIMS-BASED RISK ADJUSTMENT SCORES

    Sep 1, 1999, 00:00

  • PCN1- DIRECT AND INDIRECT TREATMENT COMPARISONS OF SECOND-GENERATION ANTIPSYCHOTIC DRUGS

    Sep 1, 1999, 00:00

  • GI2- COST-EFFECTIVENESS ANALYSIS OF HIGH DOSE IV OMEPRAZOLE INFUSION AS ADJUVANT THERAPY TO ENDOSCOPIC HAEMOSTASIS FOR BLEEDING PEPTIC ULCERS

    Sep 1, 1999, 00:00

  • TPE5- COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM

    Sep 1, 1999, 00:00

  • TPE1- ASSESSMENT OF THE APPROPRIATENESS OF CLINICAL GUIDELINES FOR CONTINUATION TREATMENT IN MAJOR DEPRESSION FROM A HEALTH ECONOMIC PERSPECTIVE

    Sep 1, 1999, 00:00

  • PCN5- THE USE OF INTERNATIONAL, DISEASE SPECIFIC, CROSS-SECTIONAL DATABASES FOR PHARMACOECONOMIC RESEARCH

    Sep 1, 1999, 00:00

  • SD2- GENERICS ONLY OR GENERICS AND EFFICIENT DRUGS?

    Sep 1, 1999, 00:00

  • CA4- METASTATIC BREAST CANCER PATIENTS TREATED WITH DOCETAXEL

    Sep 1, 1999, 00:00

  • IR1- THE HEALTH ECONOMICS OF RECLASSIFICATION OF DRUGS FROM PRESCRIPTION ONLY MEDICINES TO PHARMACY STATUS

    Sep 1, 1999, 00:00

  • TPM1- DIRECT AND INDIRECT COST OF MIGRAINE IN ITALY

    Sep 1, 1999, 00:00

  • PCA5- EVALUATION OF POTENTIAL DRUG-INDUCED CHANGES IN HEALTH CARE UTILIZATION AND ATTENDANT COSTS- MODELS, DATABASE, AND EXAMPLES

    Sep 1, 1999, 00:00

  • PMW2- THE VALUATION OF ERECTILE DYSFUNCTION- CONVERTING CLINICAL OUTCOMES INTO UTILITIES

    Sep 1, 1999, 00:00

  • Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe

    Sep 1, 1999, 00:00

  • PEN7- DIRECT COSTS OF DIABETES IN ITALY

    Sep 1, 1999, 00:00

  • PTH3- GUIDELINES FOR SUBMISSION OF REQUESTS FOR INCLUSION OF A PHARMACEUTICAL PRODUCT IN THE ISRAELI NATIONAL FORMULARY

    Sep 1, 1999, 00:00

  • TPP4- POTENTIAL COST SAVINGS BY PRESCRIPTION OF THE CHEAPEST DRUGS AMONG THOSE WITH EQUAL CONTENT IN PRIMARY CARE

    Sep 1, 1999, 00:00

  • SR5- MEDICAL EVENTS AND RESOURCE UTILISATION IN CANCER PAIN PATIENTS TREATED WITH STRONG OPIOIDS- AN ANALYSIS OF THE UK-GPRD DATABASE

    Sep 1, 1999, 00:00

  • PEN9- PHARMACODYNAMIC-PHARMACOECONOMIC (PD-PE) MODEL OF ASTHMA ANTI-INFLAMMATORY THERAPIES

    Sep 1, 1999, 00:00

  • PTH6- PATIENTS PERCEPTIONS OF THE OUTCOMES OF TREATMENT WITH TOPICAL NSAIDS, RUBIFACIANTS AND ORAL PAIN REMEDIES. A PROSPECTIVE STUDY OF MEDICINES AVAILABLE THROUGH COMMUNITY PHARMACIES

    Sep 1, 1999, 00:00

  • PCN2- DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE- RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO)

    Sep 1, 1999, 00:00

  • PTH13- THE APPLICATION OF PORTFOLIO MANAGEMENT TECHNIQUES TO PHARMACEUTICAL RD PROJECT SELECTION AND COST-EFFECTIVENESS ANALYSIS

    Sep 1, 1999, 00:00

  • Pharmacoeconomics in European Decision-Making

    Sep 1, 1999, 00:00

  • IR7- A SYSTEMATIC REVIEW OF SYSTEMIC AND TOPICAL ANTIMICROBIAL AGENTS USED IN THE PREVENTION AND TREATMENT OF CHRONIC WOUNDS

    Sep 1, 1999, 00:00

  • CV5- SIMULATED LIFETIME COSTS TO NATIONAL HEALTH SERVICE (NHS) OF BIOLOGICAL AND MECHANICAL HEART VALVE REPLACEMENT IN YOUNGER VERSUS OLDER PATIENTS

    Sep 1, 1999, 00:00

  • PCV12- ECONOMIC EVALUATION OF ACE INHIBITORS IN SPAIN

    Sep 1, 1999, 00:00

  • PEN5- METHODOLOGICAL ASPECTS OF MULTI-COUNTRY COST OF ILLNESS STUDIES-1- DATA COLLECTION INSTRUMENT DESIGN

    Sep 1, 1999, 00:00

  • PCN9- COST-EFFECTIVENESS ANALYSIS AND SOCIAL ASPECTS OF THE PALMITATE PIPOTIASINE OUTPATIENT TREATMENT IN SCHIZOPHRENIA

    Sep 1, 1999, 00:00

  • PTH8- POTENTIAL COST SAVINGS ASSOCIATED WITH ASTHMA DRUG THERAPIES USING INTEGRATED DRUG AND MEDICAL CLAIMS DATA

    Sep 1, 1999, 00:00

  • PCA4- TRANSLATION OF THE QOL-RTI HN QUESTIONNAIRE FOR ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS UNDERGOING RADIATION THERAPY FOR HEAD AND NECK CANCER

    Sep 1, 1999, 00:00

  • PCV2- THE COST-EFFECTIVENESS OF CHOLESTEROL LOWERING TREATMENT IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE- THE CASE OF A COMPREHENSIVE DIETARY INTERVENTION PROGRAM

    Sep 1, 1999, 00:00

  • PTH10- EVALUATING PHARMACEUTICAL COSTS OF PATIENTS WITH CHRONIC LUNG DISEASE IN GERMAN IN- AND OUTPATIENTS SETTING

    Sep 1, 1999, 00:00

  • TPP3- PHARMACEUTICAL CARE AND HEALTH CARE UTILIZATION

    Sep 1, 1999, 00:00

  • PTH5- A COST-MINIMIZATION ANALYSIS OF IRON DEFICIENCY ANEMIA TREATMENT

    Sep 1, 1999, 00:00

  • CN6- EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT OF HYPERTENSION UNDER EVERYDAY CIRCUMSTANCES WITH REGARD TO THE REDUCTION OF STROKE INCIDENCE

    Sep 1, 1999, 00:00

  • PTH11- APPLYING DECISIONAL ANALYSIS TO METERED DOSE INHALER MONITORING AND EDUCATIONAL OUTCOMES

    Sep 1, 1999, 00:00

  • TPE2- ECONOMIC EVALUATION OF ENOXAPARIN AS POST DISCHARGE PROPHYLAXIS FOR DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE HIP SURGERY

    Sep 1, 1999, 00:00

  • SR1- THE ECONOMIC IMPACT OF TOLTERODINE IN PORTUGAL

    Sep 1, 1999, 00:00

  • CA5- QUALITY OF LIFE IN A BREAST CANCER POPULATION UNDERGOING ADJUVANT TREATMENT

    Sep 1, 1999, 00:00

  • CV8- DETERMINANTS OF DISCONTINUATION OF NEW COURSES OF ANTIHYPERTENSIVE MEDICATIONS

    Sep 1, 1999, 00:00

  • PCV5- MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD) PATIENTS- MODELLING THE RISK OF ISCHEMIC EVENTS AND THEIR ECONOMIC CONSEQUENCES

    Sep 1, 1999, 00:00

  • PG13- DIFFERENTIAL COST OF USING NSAIDS IN A MEDICAID POPULATION

    Sep 1, 1999, 00:00

  • TPQ1- THE EUROPEAN REGULATORY ISSUES ON QUALITY OF LIFE ASSESSMENT (ERIQA) PROJECT

    Sep 1, 1999, 00:00

  • QL2- PSYCHOMETRIC EQUIVALENCE EVALUATION OF FIVE NON-WESTERN-LANGUAGE TRANSLATED VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) VERSION 4

    Sep 1, 1999, 00:00

  • QL1- THE QUALITY OF LIFE OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY- PREDICTORS AND RELEVANCE TO MANAGEMENT COMPLIANCE

    Sep 1, 1999, 00:00

  • IR6- DEVELOPMENT AND PRELIMINARY RESULTS OF THE HEALTH AND ECONOMIC CONSEQUENCES OF SMOKING MODEL

    Sep 1, 1999, 00:00

  • PID4- COST-EFFECTIVENESS OF PARTNER PHARMACOTHERAPY IN SCREENING FOR CHLAMYDIA TRACHOMATIS

    Sep 1, 1999, 00:00

  • IR8- COST-EFFECTIVENESS OF COMBINED HEPATITIS A AND B VACCINATION AND HEPATITIS B MONOVACCINATION IN SWITZERLAND AND AUSTRIA

    Sep 1, 1999, 00:00

  • PID3- HOSPITALIZATION RATES AND ASSOCIATED COSTS FOR INFLUENZA IN A MANAGED CARE POPULATION

    Sep 1, 1999, 00:00

  • PMW3- ECONOMICAL ANALYSIS OF THE RESULTS OF PROSTATE CANCER SCREENING PROGRAM

    Sep 1, 1999, 00:00

  • PCN11- UK SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (UK-SCAP)-A PROSPECTIVE, OBSERVATIONAL STUDY OF THE TREATMENT AND OUTCOMES OF DRUG THERAPY FOR SCHZOPHRENIA IN A NATURALISTIC SETTING

    Sep 1, 1999, 00:00

  • PEN6- COSTS OF TREATING NAIVE PATIENTS WITH TYPE 2 DIABETES-A COMPARISON BETWEEN THE UNITED KINGDOM AND FRANCE

    Sep 1, 1999, 00:00

  • PCV8- HOSPITALIZATION PROFILE OF PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER- AN ADMINISTRATIVE DATABASE ANALYSIS

    Sep 1, 1999, 00:00

  • SR4- LONGITUDINAL ASSESSMENT OF ASTHMA AND WORK OUTCOMES

    Sep 1, 1999, 00:00

  • TPL1- STATE OF THE ART IN PHARMACOECONOMIC EVALUATION- A REVIEW OF METHODS AND PRACTICE

    Sep 1, 1999, 00:00

  • CV1- LONG TERM COMPLIANCE WITH ANTIHYPERTENSIVE DRUG THERAPY IN A MANAGED CARE ORGANIZATION

    Sep 1, 1999, 00:00

  • TPE4- DEVELOPMENT OF A QUALITY ASSESSMENT CHECKLIST FOR THE APPRAISAL OF ECONOMIC MODELS- A CASE-STUDY IN OSTEOPOROSIS

    Sep 1, 1999, 00:00

  • TPQ4- A EUROPEAN EQ-5D VALUE SET. MYTH OR REALITY?

    Sep 1, 1999, 00:00

  • The Norwegian Version of the Psoriasis Disability Index — A Validation and Reliability Study

    Sep 1, 1999, 00:00

  • TPQ5- MAPI RESEARCH INSTITUTE HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROJECT

    Sep 1, 1999, 00:00

  • CV3- A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL AS TREATMENT FOR HYPERTENSION IN THE UNITED STATES

    Sep 1, 1999, 00:00

  • PEN8- CODE-2 UK- THE CURRENT COSTS OF TYPE-2 DIABETES IN THE UK

    Sep 1, 1999, 00:00

  • CV7- AMLODIPINE REDUCES HOSPITALIZATION ASSOCIATED WITH TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH CLINICAL CORONARY ARTERY DISEASE

    Sep 1, 1999, 00:00

  • PMW1- COSTS OF TREATMENT WITH DOXAZOSIN VERSUS TAMSULOSIN IN MEN WITH BENIGN PROSTATIC HYPERPLASIA

    Sep 1, 1999, 00:00

  • PG12- DIAGNOSIS AND TREATMENT OF CONSTIPATION IN A MANAGED CARE POPULATION

    Sep 1, 1999, 00:00

  • PCA3- TREATMENT PATHWAYS, RESOURCE USE AND COSTS IN THE MANAGEMENT OF SMALL CELL LUNG CANCER

    Sep 1, 1999, 00:00

  • IR4- BUDESONIDE GAVE LOWER HEALTH CARE COSTS IN ASTHMA TREATMENT THAN FLUTICASONE PROPIONATE

    Sep 1, 1999, 00:00

  • TPC1- COST-EFFECTIVENESS ANALYSIS OF BUDESONIDE VERSUS DISODIUM CROMOGLYCATE THERAPY IN CHILDREN WITH MODERATE BRONCHIAL ASTHMA

    Sep 1, 1999, 00:00

  • IR5- DECISION ANALYSIS OF ACUTE TONSILLOPHARYNGITIS MANAGEMENT IN RUSSIAN CHILDREN

    Sep 1, 1999, 00:00

  • PG14- COST OF ITALIAN DYSPEPTIC PATIENTS- A FEASIBILITY STUDY FROM THE DYSPEPSIA PROJECT

    Sep 1, 1999, 00:00

  • An Analysis of the Impact of Demographic, Clinical, and Social Factors on Health-Related Quality of Life

    Jul 1, 1999, 00:00

  • Towards a European Consensus on Conducting and Reporting Health Economic Evaluations—A Report from the ISPOR Inaugural European Conference

    Jul 1, 1999, 00:00

  • Assessment of Quality of Care for Managed Care and Fee-For-Service Patients Based on Analysis of Avoidable Hospitalizations

    Jul 1, 1999, 00:00

  • The Role of SSRI Antidepressants for Treating Depressed Patients in the California Medicaid (Medi-Cal) Program

    Jul 1, 1999, 00:00

  • Cost-Effectiveness of Prolonged Administration of a Low Molecular Weight Heparin for the Prevention of Deep Venous Thrombosis Following Total Hip Replacement

    Jul 1, 1999, 00:00

  • Comparing the Quality of Care Provided by Health Plans- Are the Data There?

    Jul 1, 1999, 00:00

  • Postmarketing Studies- Benefits and Risks

    Jul 1, 1999, 00:00

  • PPO12- EFFECT OF PLAN CHARACTERISTICS ON THE COST OF PHARMACEUTICALS IN A PRIVATE THIRD-PARTY PRESCRIPTION PROGRAM

    May 1, 1999, 00:00

  • PAD8- INTERPRETATION OF HAQ DISABILITY INDEX IMPROVEMENT AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS IN RANDOMIZED CLINICAL TRIALS

    May 1, 1999, 00:00

  • DP4- USING COST OF ILLNESS STUDIES IN HEALTHCARE POLICY-MAKING

    May 1, 1999, 00:00

  • PKU2- IMPROVEMENTS IN CLINICAL OUTCOMES, HEALTH-RELATED QUALITY OF LIFE (HRQoL) AND SYMPTOM BOTHER FOR OVERACTIVE BLADDER PATIENTS TREATED WITH A NEW ONCE-DAILY FORMULATION OF OXYBUTYNIN

    May 1, 1999, 00:00

  • DM1- RANDOMIZED EVALUATION OF A DISEASE MANAGEMENT PROGRAM FOR DYSPEPSIA IN A MANAGED CARE SETTING

    May 1, 1999, 00:00

  • POR4- LINGUISTIC VALIDATION OF THE SLICE/LIFE QUESTIONNAIRE

    May 1, 1999, 00:00

  • CD2- ABCIXIMAB IN PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY- A MULTICENTER OBSERVATIONAL STUDY

    May 1, 1999, 00:00

  • TPS7- PREVENTION OF RUBELLA INFECTION IN CRUISE SHIP CREW MEMBERS- A COST ANALYSIS COMPARING TWO INTERVENTIONS

    May 1, 1999, 00:00

  • PWM4- THE RELATIONSHIP BETWEEN NOTTINGHAM HEALTH PROFILE DOMAINS AND CLINICAL CHARACTERISTICS OF WOMEN WITH ESTABLISHED POSTMENOPAUSAL OSTEOPOROSIS

    May 1, 1999, 00:00

  • WPE1- MODELING FOR POLICY-MAKERS THE EXPECTED BENEFITS OF PREVENTION

    May 1, 1999, 00:00

  • PID12- THE RATE OF INFECTIONS CONCURRENT WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA

    May 1, 1999, 00:00

  • TPCP1- THE ROLE OF COMPLIANCE IN THERAPY CHANGES AMONG NEWLY DIAGNOSED DIABETIC PATIENTS

    May 1, 1999, 00:00

  • RM2- COSTS OF HEALTHCARE FOR 8 YEARS PRIOR TO RECOGNITION OF TYPE 2 DIABETES (DM2)

    May 1, 1999, 00:00

  • PAD3- RESPONSIVENESS OF WOMAC IMPROVEMENT TO PATIENTS PhGA) OF IMPROVEMENT AMONG OSTEOARTHRITIS PATIENTS (OA)

    May 1, 1999, 00:00

  • TPIL4- SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP)- INITIAL FINDINGS ON HEALTHCARE RESOURCE UTILIZATION IN AUSTRALIA

    May 1, 1999, 00:00

  • ER3- OSTEOPOROSIS MARKOV MODEL- EVALUATING THE IMPACT OF DISCOUNTING AND AGE-ADJUSTED FRACTURE RATES ON COST-EFFECTIVENESS RATIOS AND MARKOV ANALYSIS

    May 1, 1999, 00:00

  • PNP12- DIRECT MEDICAL COST DIFFERENCES BETWEEN ALZHEIMERS PATIENTS IN A MANAGED CARE ORGANIZATION

    May 1, 1999, 00:00

  • TPDM1- ASSESSING THE PREDICTIVE ABILITY OF A DETERMINISTIC MODEL AND STOCHASTIC MODEL

    May 1, 1999, 00:00

  • PID18- THE COST OF INFLUENZA IN THE EMERGENCY ROOM AND HOSPITAL

    May 1, 1999, 00:00

  • PCD13- PATIENT BENEFIT QUESTIONNAIRE (PBQ) FOR XEROSTOMIA- DEVELOPMENT AND VALIDATION REPORT

    May 1, 1999, 00:00

  • TPCT1- ECONOMIC ANALYSIS OF TIRILAZAD MESYLATE FOR ANEURYSMAL SUBARACHNOID HEMORRHAGE- ECONOMIC EVALUATION COMBINING FOUR PHASE III CLINICAL TRIALS

    May 1, 1999, 00:00

  • TPIL6- ESTIMATING THE ECONOMIC IMPACT (EI) OF VIRAL MENINGITIS (VM) IN THE UNITED STATES (US)

    May 1, 1999, 00:00

  • PCVD1- A COMPARISON OF THE EMEA AND FDA DRAFT GUIDELINES IN CONGESTIVE HEART FAILURE (CHF) WITH PARTICULAR REFERENCE TO QUALITY OF LIFE (QOL) OUTCOMES

    May 1, 1999, 00:00

  • TPDM4- MODELING LIFETIME TREATMENT COSTS OF HIV/AIDS PATIENTS

    May 1, 1999, 00:00

  • WMD4- COMBINING MARKET DATA AND STATEDPREFERENCE DATA TO ESTIMATE DEMAND FOR A NEW PHARMACEUTICAL

    May 1, 1999, 00:00

  • TPS4- COMPARISON OF THE EFFECTIVENESS OF INNOVATIVE PROGRAMS TO ENHANCE MAMMOGRAPHY COMPLIANCE- A META-ANALYSIS

    May 1, 1999, 00:00

  • TPCP7- A PATH ANALYTIC STUDY OF THE ASSOCIATION BETWEEN PHARMACISTS DIRECTIVE GUIDANCE BEHAVIORS, PATIENT SATISFACTION, PATIENT COMPLIANCE, AND HEALTH-RELATED QUALITY OF LIFE (HRQoL)

    May 1, 1999, 00:00

  • PWM1- COMPARATIVE CLINICAL ECONOMICS OF THE INTRAUTERINE LEVONORGESTRELRELEASING SYSTEM MIRENA IN WOMEN REQUIRING CONTRACEPTION

    May 1, 1999, 00:00

  • WPE4- AN ELECTRONIC TOOL FOR EMPIRIC ASSESSMENT OF DISEASE RISK, CATEGORIZATION OF PATIENTS AT RISK AND MONITORING OF OUTCOMES

    May 1, 1999, 00:00

  • PDD3- A COST-OF-TREATMENT MODEL FOR TYPE 2 DIABETES

    May 1, 1999, 00:00

  • PRD2- A TELEPHONE-BASED APPROACH FOR MONITORING HEALTH STATUS IN ASTHMA DISEASE MANAGEMENT

    May 1, 1999, 00:00

  • TPDM3- IS THERE POTENTIAL BIAS IN MODELING WITH DECISION ANALYTIC SOFTWARE OR MATRIX PROGRAMMING?

    May 1, 1999, 00:00

  • PHARMACOECONOMICS- OF SCREENING AND TESTING

    May 1, 1999, 00:00

  • PNP1- DEVELOPMENT AND INITIAL VALIDATION OF A BRIEF MENTAL HEALTH OUTCOME MEASURE

    May 1, 1999, 00:00

  • PRD14- A PHARMACOECONOMIC EVALUATION OF BUDESONIDE AQUEOUS NASAL SPRAY AND FLUTICASONE PROPIONATE NASAL SPRAY IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS

    May 1, 1999, 00:00

  • WPE9- BEGIN WITH THE END IN MIND- ISSUES IN PLANNING PHARMACOECONOMIC RESEARCH FOR MORE EFFECTIVE COMMUNICATION

    May 1, 1999, 00:00

  • PID1- COST-EFFECTIVENESS ANALYSIS OF RECOMBINANT HUMAN ERYTHROPOIETIN VERSUS TRANSFUSION IN HIV PATIENTS TREATED WITH ZIDOVUDINE

    May 1, 1999, 00:00

  • PCP3- THE ECONOMIC COST OF ACETAMINOPHENRELATED LIVER TOXICITY TO THE CALIFORNIA MEDICAID PROGRAM

    May 1, 1999, 00:00

  • PUP5- ECONOMIC IMPACT OF PRESCRIBING IN THE URBAN COMMUNITY OF DELHI

    May 1, 1999, 00:00

  • PG12- OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN FOR H. PYLORI ERADICATION PRODUCES GREATEST COST SAVINGS IN MALAYSIAN DUODENAL ULCER PATIENTS

    May 1, 1999, 00:00

  • PNP4- ECONOMIC OUTCOMES OF ANTIDEPRESSANT USE IN A MANAGED CARE ORGANIZATION

    May 1, 1999, 00:00

  • RD3- CYSTIC FIBROSIS- AGGRESSIVE INTERVENTION IS ASSOCIATED WITH IMPROVED OUTCOME

    May 1, 1999, 00:00

  • WDM2- EXPERIENCE WITH RESEARCH DATA

    May 1, 1999, 00:00

  • TPCT6- INCREASED UPPER GASTROINTESTINAL (UGI) DISTRESS AMONG ARTHRITIS PATIENTS TREATED WITH NSAIDS AS COMPARED TO CELECOXIB AND PLACEBO

    May 1, 1999, 00:00

  • PG16- SEQUENCING OF TREATMENTS IN VARICEAL BLEEDING

    May 1, 1999, 00:00

  • PPR4- DEVELOPING METHODOLOGICAL STANDARDS IN PHARMACOECONOMIC RESEARCH- AN APPROACH BY A TASK FORCE OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

    May 1, 1999, 00:00

  • PRD9- THE HEALTHCARE UTILIZATION OF PATIENTS WITH CHRONIC SINUSITIS

    May 1, 1999, 00:00

  • PNP16- ANTIPSYCHOTIC DRUG USE PATTERNS AND THE COST OF TREATING SCHIZOPHRENIA OVER A 2-YEAR PERIOD

    May 1, 1999, 00:00

  • PCVD11- FORMULARY ANALYSIS OF ANGIOTENSIN II ANTAGONISTS IN A UK TEACHING HOSPITAL

    May 1, 1999, 00:00

  • PRD3- DEVELOPMENT OF AN ASTHMA QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE AMERICAN ADULTS (AQLQ-NAA)

    May 1, 1999, 00:00

  • PWM2- EFFECTIVENESS AND COST IMPACT OF EMERGENCY CONTRACEPTION OBTAINED FROM A PHARMACIST IN WASHINGTON STATE

    May 1, 1999, 00:00

  • TPQL3- QUALITY OF LIFE IN CROHN DISEASE- A PROSPECTIVE, LONGITUDINAL STUDY IN 231 PATIENTS

    May 1, 1999, 00:00

  • WMD1- DATA COLLECTION METHODS FOR RESOURCE UTILIZATION- CHOOSING THE RIGHT APPROACH

    May 1, 1999, 00:00

  • PID15- INFLUENCE OF MOTIVATING FACTORS AND BARRIERS ON INFLUENZA VACCINATION IN AN EMPLOYED POPULATION

    May 1, 1999, 00:00

  • TPRD3- OUTCOMES OF TREATMENT OF UNCOMPLICATED HYPERTENSION WITH DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS

    May 1, 1999, 00:00

  • PID5- DEVELOPMENT AND INITIAL ASSESSMENT OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE-7 FOR USE IN INTERNATIONAL HIV STUDIES

    May 1, 1999, 00:00

  • PCD4- THE VALUE OF HOME CARE IN METASTATIC BREAST CANCER MANAGEMENT- MODELING ORAL VERSUS INTRAVENOUS CHEMOTHERAPY AT HOME AND AT AN OUTPATIENT CLINIC

    May 1, 1999, 00:00

  • PNP22- HYPNOTIC DRUGS CONSUMPTION IN RUSSIA

    May 1, 1999, 00:00

  • TPIL3- THE MEDICAL COST OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS- METHODS AND EVIDENCE

    May 1, 1999, 00:00

  • TPIC4- QUANTIFICATION OF INDIRECT BENEFITS FROM MORBIDITY AND MORTALITY REDUCTION- APPLICATION TO PHARMACY SERVICES PROGRAM EVALUATION

    May 1, 1999, 00:00

  • ER2- PRICE ELASTICITY OF PEOPLES WILLINGNESS TO PAY IN PATIENTS WITH URINARY INCONTINENCE

    May 1, 1999, 00:00

  • PG13- PRESCRIPTION TO OVER-THE-COUNTER PRODUCTS- HISTAMINE-2-RECEPTOR ANTAGONISTS IN THE UK

    May 1, 1999, 00:00

  • ND3- AN OUTCOMES MEASURE FOR NON-INSTITUTIONALIZED SCHIZOPHRENIC CONSUMERS

    May 1, 1999, 00:00

  • PPO9- USING OUTCOMES RESEARCH TO DEMONSTRATE QUALITY IMPROVEMENT FOR NCQA ACCREDITATION- A CASE STUDY

    May 1, 1999, 00:00

  • PCVD10- ATTAINMENT OF LIPID GOALS IN PATIENTS TREATED WITH HMG-COA REDUCTASE INHIBITORS- A RETROSPECTIVE STUDY

    May 1, 1999, 00:00

  • CD4- LEFT VENTRICULAR SYSTOLIC FUNCTION AND 90-DAY HOSPITAL READMISSION IN CONGESTIVE HEART FAILURE PATIENTS- IMPLICATIONS FOR DISEASE MANAGEMENT

    May 1, 1999, 00:00

  • POR2- PSYCHOMETRIC EVALUATION OF THE PATIENT MEDICATION ADHERENCE QUESTIONNAIRE

    May 1, 1999, 00:00

  • PKU6- COST-EFFECTIVENESS ANALYSIS OF MYCOPHENOLATE MOFETIL TREATMENT FOR INTRACTABLE ACUTE REJECTION IN RENAL TRANSPLANTATION RECIPIENTS

    May 1, 1999, 00:00

  • PPR3- THE ROLE OF PHARMACOECONOMIC INVESTIGATIONS IN CREATING THE PATIENTS TREATMENT RECORD

    May 1, 1999, 00:00

  • ND4- ASSESSING UTILITIES FOR DEPRESSION OUTCOMES- PREFERENCES OF DEPRESSED PATIENTS AND THE GENERAL PUBLIC

    May 1, 1999, 00:00

  • PCD10- DIFFERENCES IN END-OF-LIFE MEDICAL CARE COSTS FOR PROSTATE CANCER PATIENTS- RESULTS FROM THE CaPSURE DATABASE

    May 1, 1999, 00:00

  • PNP18- USE OF ANTIPSYCHOTIC MEDICATIONS AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA

    May 1, 1999, 00:00

  • TPCT7- CEFPODOXIME PROXETIL 100mg VERSUS CEFPODOXIME PROXETIL 200mg IN THE TREATMENT OF ACUTE BACTERIAL EXACERBATION OF CHRONIC BRONCHITIS IN ADULT PATIENTS

    May 1, 1999, 00:00

  • PCP6- OPIOID ANALGESICS USE IN PATIENTS WITH NONMALIGNANT PAIN- SELECTING AN APPROPRIATE COMPARISON GROUP

    May 1, 1999, 00:00

  • TPIL1- ANALYSIS OF DIRECT, INDIRECT, AND TOTAL COSTS OF ASTHMA FROM PATIENT SURVEY DATA

    May 1, 1999, 00:00

  • TPRD5- USING HOSPITAL CLAIMS TO TRACK PRACTICE PATTERNS, OUTCOMES, AND COSTS IN PERCUTANEOUS CORONARY INTERVENTIONS (PCI)

    May 1, 1999, 00:00

  • TPIL2- THE COST OF TREATING PARKINSONS DISEASE (PD) IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM

    May 1, 1999, 00:00

  • ID3- ADDITIONAL ANTIBIOTIC UTILIZATION IN A RANDOMIZED TRIAL OF CLARITHROMYCIN (CLARI) COMPARED WITH AZITHROMYCIN (AZI) FOR THE TREATMENT OF S. PYOGENES PHARYNGITIS/TONSILLITIS

    May 1, 1999, 00:00

  • PPO1- THE ROLE OF QUALITY OF LIFE INFORMATION IN MANAGED CARE DECISION-MAKING

    May 1, 1999, 00:00

  • TPRD6- TOTAL HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MIGRAINE IN A MEDICAID POPULATION

    May 1, 1999, 00:00

  • PID11- COST-EFFECTIVENESS OF FIVE ORAL ANTIMICROBIALS FOR ACUTE OTITIS MEDIA

    May 1, 1999, 00:00

  • POR9- CLINICAL EPIDEMIOLOGY PRINCIPLES OF AND THE COST OF DRUG TRIALS

    May 1, 1999, 00:00

  • PCD11- COST-EFFECTIVENESS OF THE THERAPY WITH IODINE 125-SEED IMPLANTATION IN PATIENTS WITH STAGE T1 AND T2 PROSTATE CARCINOMA IN COMPARISON TO TOTAL PROSTATECTOMY AND BEAM RADIATION IN 3D-TECHNIQUE

    May 1, 1999, 00:00

  • PNP10- COST-BENEFIT ANALYSIS OF FLUOXETINE INCLUSION IN THE MEDI-CAL FORMULARY

    May 1, 1999, 00:00

  • CD3- EXCESS STROKE AMONG HYPERTENSIVE MEN AND WOMEN ATTRIBUTABLE TO UNDERTREATMENT OF HYPERTENSION

    May 1, 1999, 00:00

  • PWM3- IMPLICATIONS OF MENOPAUSAL SYMPTOMS ON QUALITY OF LIFE

    May 1, 1999, 00:00

  • PUP1- PHARMACOECONOMICS IN RUSSIA- FIRST STEPS

    May 1, 1999, 00:00

  • PWM5- COMPARISON OF QUALITY OF LIFE SCORES BETWEEN MENOPAUSAL WOMEN AND AGEMATCHED PEERS

    May 1, 1999, 00:00

  • PDD1- DISEASE MANAGEMENT PATTERNS OF TYPE 2 DIABETIC PATIENTS IN AN ACADEMIC FAMILY MEDICINE CENTER

    May 1, 1999, 00:00

  • TPS5- COST-EFFECTIVENESS ANALYSIS OF GENETIC TESTING FOR BREAST CANCER

    May 1, 1999, 00:00

  • WMM1- IS THE CURRENT RELIANCE ON THE MARKOV ASSUMPTION IN ECONOMIC MODELS JUSTIFIED?

    May 1, 1999, 00:00

  • PCD12- COST OF MANAGING MUCOSITIS AND XEROSTOMIA IN HEAD AND NECK CANCER PATIENTS UNDERGOING CHEMORADIOTHERAPY (CRT) OR RADIATION (RT)

    May 1, 1999, 00:00

  • TPRD4- THE COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION

    May 1, 1999, 00:00

  • PID6- HEALTH-RELATED QUALITY OF LIFE CHANGES IN PATIENTS WITH ONYCHOMYCOSIS

    May 1, 1999, 00:00

  • PID14- ECONOMIC ANALYSIS OF ANTIMICROBIAL AGENTS FOR HOSPITAL-ACQUIRED PNEUMONIA

    May 1, 1999, 00:00

  • TPS3- ESTIMATING THE VALUE OF DOUBLE READING IN MAMMOGRAPHY SCREENING

    May 1, 1999, 00:00

  • PRD10- COST-EFFECTIVENESS OF AZITHROMYCIN AND CO-AMOXICLAV IN ACUTE SINUSITIS

    May 1, 1999, 00:00

  • PNP2- IMPACT OF CLINICIAN EDUCATION ON LONG-TERM ANTIDEPRESSANT PRESCRIBING

    May 1, 1999, 00:00

  • PWM8- COST-EFFECTIVENESS OF VIAGRA VERSUS MUSE IN THE TREATMENT OF MALE ERECTILE DYSFUNCTION

    May 1, 1999, 00:00

  • PCVD8- SELECTIVE USE OF CALCIUM ANTAGONISTS FOR HIGH-RISK HYPERTENSIVES

    May 1, 1999, 00:00

  • PRD13- DEVELOPMENT OF A NASAL COMFORT INDEX FOR NASAL SPRAYS IN ADULTS WITH SEASONAL ALLERGIC RHINITIS

    May 1, 1999, 00:00

  • PID10- DEVELOPMENT AND VALIDATION OF A DECISION ANALYTIC FRAMEWORK (DAF) TO EVALUATE THE ECONOMIC IMPACT OF SUSPECTED MENINGITIS (SM)

    May 1, 1999, 00:00

  • PID4- A RETROSPECTIVE DATABASE STUDY OF AIDS INITIAL TREATMENT REGIMENS, SWITCHING PATTERNS, AND PATIENT ADHERENCE

    May 1, 1999, 00:00

  • ND1- INPATIENT COST AND RESOURCE UTILIZATION FOR PARKINSONS DISEASE

    May 1, 1999, 00:00

  • PPO5- PHARMACIST ASSESSMENT OF THE VALUE OF PROVIDING PHARMACEUTICAL CARE IN THE COMMUNITY PHARMACY SETTING

    May 1, 1999, 00:00

  • WMS5- ASSESSING THE GENERALIZABILITY OF THE RESULTS OF MULTINATIONAL TRIALS FOR INDIVIDUAL COUNTRIES PARTICIPATING IN THE TRIAL

    May 1, 1999, 00:00

  • PID20- SAVINGS IN DIRECT MEDICAL COSTS PRODUCED BY AN INHALED SOLUTION OF TOBRAMYCIN (TOBI) IN CHILDREN WITH CYSTIC FIBROSIS

    May 1, 1999, 00:00

  • PCVD7- IDENTIFICATION OF COMOROBIDITIES AMONG A HYPERTENSIVE POPULATION USING ADMINISTRITATIVE CLAIMS AND MEDICAL RECORDS DATA

    May 1, 1999, 00:00

  • WPE2- THE NUTS AND BOLTS OF CONDUCTING RANDOMIZED OUTCOMES TRIALS

    May 1, 1999, 00:00

  • PID16- ECONOMIC STUDY OF CEPHALOSPORINS IN THE TREATMENT OF MODERATE LOWER RESPIRATORY TRACT INFECTION

    May 1, 1999, 00:00

  • PCD2- COSTS ASSOCIATED WITH CHEMOTHERAPY-INDUCED TOXICITIES- A REVIEW OF THE LITERATURE

    May 1, 1999, 00:00

  • PID3- ECONOMIC EVALUATION OF SYSTEMIC TREATMENTS FOR CMV RETINITIS IN PERSONS WITH AIDS IN SWITZERLAND

    May 1, 1999, 00:00

  • TPIL5- EVALUATION OF MEDICAL RESOURCE UTILIZATION IN ALZHEIMERS DISEASE

    May 1, 1999, 00:00

  • TPIC1- INDIRECT COSTS OF MIGRAINEURS- THREE DIFFERENT APPROACHES TO VALUING LOST WORKPLACE PRODUCTIVITY

    May 1, 1999, 00:00

  • WTG3- WHAT EVERY OUTCOMES RESEARCHER SHOULD KNOW ABOUT WOMENS HEALTH RESEARCH

    May 1, 1999, 00:00

  • TPCP3- PATIENT COMPLIANCE, QUALITY OF LIFE, AND SATISFACTION AFTER INTENSIVE OUTPATIENT COUNSELING

    May 1, 1999, 00:00

  • WTG2- UPDATE ON THE SCRIPT PROJECT

    May 1, 1999, 00:00

  • WTG6- MAKING DECISIONS ABOUT ANTIBIOTIC RESISTANCE

    May 1, 1999, 00:00

  • WMS1- ESTIMATING MEDICAL COSTS FROM INCOMPLETE FOLLOW-UP DATA

    May 1, 1999, 00:00

  • PAD1- EFFICACY OF AN INTERVENTION TO RATIONALIZE PRESCRIBING OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)

    May 1, 1999, 00:00
  • «
  • 171
  • 172
  • 173 (current)
  • 174
  • 175